References
- van der Linden S, van der Heijde D. Ankylosing spondylitis. Clinical features. Rheum. Dis. Clin. North Am. 24, 663–676 (1998).
- van der Linden SM, Valkenburg HA, de Jongh BM, Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum. 27, 241–249 (1984).
- Braun J, Bollow M, Remlinger G et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 41, 58–67 (1998).
- Gran JT, Husby G, Hordvik M. Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Ann. Rheum. Dis. 44, 359–367 (1985).
- Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis. Results from the German rheumatological database. German Collaborative Arthritis Centers. J. Rheumatol. 27, 613–622 (2000).
- Davis JC Jr, Van Der Heijde D, Braun J et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 48, 3230–3236 (2003).
- Gorman JD, Sack KE, Davis JC. Etanercept in the treatment of ankylosing spondylitis: a randomized, double-blind, placebo-controlled study. N. Engl. J. Med. 346, 1349–1356 (2002).
- Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359, 1187–1193 (2002).
- Drummond MF, O’Brien BJ. Methods For The Economic Evaluation Of Healthcare Programmes. Oxford Medical Publications, Oxford, UK (1997).
- Sanchez LA. Applied pharmacoeconomics: evaluation and use of pharmacoeconomic data from the literature. Am. J. Health Syst. Pharm. 56, 1630–1640 (1999).
- Merkesdal S, Ruof J, Huelsemann JL et al. Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis. J. Rheumatol. 28, 657–661 (2001).
- Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritus Rheum. 46, 223–231 (2002).
- Kobelt G, Andlin-Sobocki P, Brophy S, Jonsson L, Calin A, Braun J. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (RemicadeR). Rheumatology 43, 1158–1166 (2004).
- Boonen A, van der Heijde D, Landewe R et al. Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann. Rheum. Dis. 62, 732–740 (2003).
- Boonen A, van der Heijde D, Landewe R et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann. Rheum. Dis. 61, 429–437 (2002).
- Boonen A, Van Den Heuvel R, Van Tubergen A et al. Large differences in cost-of-illness and well being between patients with fibromyalgia, chronic low back pain or ankylosing spondylitis. Ann. Rheum. Dis. 64(3), 396–402 (2005).
- Sailly JC, Lebrun T. Les consequences economiques et sociales de la pelvispondylite rhumatismale. Rev. Epidemiol. Sante Publique 30, 305–324(1982).
- Van Tubergen A, Boonen A, Landewé R et al. Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum. 47, 459–467 (2002).
- Koopmanschap MA, Rutten FFH. A practical guide for calculating the indirect costs of disease. PharmacoEconomics 10, 460–466 (1996).
Website
- OECD purchasing power parities www.oecd.com (Accessed March 2005)